Tilray Brands (TLRY) Interest & Investment Income (2018 - 2024)
Tilray Brands (TLRY) posted Interest & Investment Income of $12.8 million for Q2 2024, down 86.54% on a QoQ basis from $95.3 million in Q1 2023.
Tilray Brands (TLRY) Interest & Investment Income (2018 - 2024) Analysis & Trends
Tilray Brands' Interest & Investment Income history runs 6 years deep, the most recent figure standing at $12.8 million for Q2 2024.
- Quarterly Interest & Investment Income changed N/A year-over-year to $12.8 million in Q2 2024, while the trailing twelve-month figure through May 2024 was $12.8 million (down 82.93% YoY) and the FY2024 annual result came in at $12.8 million, down 82.93% from the prior year.
- Interest & Investment Income was $12.8 million for Q2 2024 at Tilray Brands, down from $95.3 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $95.3 million in Q1 2023 and bottomed at -$39.3 million in Q1 2022.
- A 4-year average of $2.1 million and a median of -$8.9 million in 2022 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2022 — Interest & Investment Income slumped 289.06% — and 2023, when it soared 342.63%.
- Tilray Brands' Interest & Investment Income stood at -$16.3 million in 2021, then dropped by 8.21% to -$17.6 million in 2022, then surged by 640.41% to $95.3 million in 2023, then sank by 86.54% to $12.8 million in 2024.
- Business Quant data shows TLRY's Interest & Investment Income at $12.8 million in Q2 2024, $95.3 million in Q1 2023, and -$17.6 million in Q4 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 32.85 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 41.80 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 28.10 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Tilray Brands | 454.65 Mn | 394.45 Mn | 54.95 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2024 | 12.83 Mn |
| Feb 28, 2023 | 95.35 Mn |
| Nov 30, 2022 | -17.64 Mn |
| Aug 31, 2022 | -2.53 Mn |
| May 31, 2022 | -15.18 Mn |
| Feb 28, 2022 | -39.30 Mn |
| Nov 30, 2021 | -16.31 Mn |
| Aug 31, 2021 | -649,000.00 |
| Dec 31, 2019 | 207,000.00 |
| Sep 30, 2019 | 210,000.00 |
| Mar 31, 2019 | 135,000.00 |
| Sep 30, 2018 | 170,000.00 |
| Jun 30, 2018 | 5,000.00 |
| Mar 31, 2018 | 1,000.00 |